A Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt

Sponsor
Xijing Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03444246
Collaborator
(none)
60
1
2
15
4

Study Details

Study Description

Brief Summary

To clarify the influence of iodine intake in salt on the incidence and treatment of hyperthyroidism patients, so as to provide theoretical basis for accurate formulation of iodine intake in salt, and provide strategies for effective prevention and control of hyperthyroidism.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Iodine free diet group
  • Dietary Supplement: Normal iodine diet group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Parallel, Double-blind, Randomized Controlled Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt
Anticipated Study Start Date :
Mar 1, 2018
Anticipated Primary Completion Date :
Mar 1, 2019
Anticipated Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Iodine free diet group

The arm with non iodized salt,the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.

Dietary Supplement: Iodine free diet group
120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.

Dietary Supplement: Normal iodine diet group
120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.

Active Comparator: Normal iodine diet group

The arm with iodized salt,the subject in the control group were consumed with iodized salt within six months.

Dietary Supplement: Normal iodine diet group
120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.

Outcome Measures

Primary Outcome Measures

  1. Compare the recurrence rate of hyperthyroidism in the two groups [The recurrence rate of hyperthyroidism in the two groups was compared after the first six months of the trial.]

    The patients were randomly divided into the non-iodine diet group, the normal iodine diet group, and the two groups were given routine anti-thyroid medication for 6 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. sign informed consent before any research procedure is carried out

  2. men or women aged 18-65 (equal) at the age of 1.

  3. had been diagnosed as Graves hyperthyroidism

  4. patients with hyperthyroidism who had not been treated with drugs or stopped taking medicine for more than 3 months

  5. reduction to the current dose of hyperthyroidism for more than 2 months

Exclusion Criteria:
  1. during the period of pregnancy and lactation, those who plan to be pregnant during the study are not granted medical permission.

Effective contraceptives

  1. for the last 1 months or the need for long-term use of amiodarone

  2. the history of anaphylaxis (such as systemic anaphylaxis, vasoedema, epidermal exfoliation) Etc.)

  3. consecutive use of beta receptor blockers for the last 2 weeks

  4. over the past six months, systemic use of corticosteroids (oral or intravenous) is continuous More than 7 days

  5. there was an obvious liver disease, showing one of the following cases: two consecutive weeks before A. visits.

It was confirmed that the measurements of AST or ALT were more than 3 times higher than the highest normal value (local data).

  1. bilirubin synthesis and / or excretion disorders (such as hyperbilirubinemia), and other Decompensated liver diseases such as coagulation disorders, hepatic encephalopathy, hypoproteinemia, ascites, and esophagus Bleeding from varicose veins. C. acute viral, active, alcoholic, and alcoholic Other types of hepatitis 7 visits for 4 weeks before the 1 (or the local data), leukopenia (less than 3 * 10 9 /L) B/ 0 edition of the First Affiliated Hospital of The Fourth Military Medical University The First Affiliated Hospital, the Fourth Military Medical University B/0 Edition Seventh pages / 13 Pages Or neutropenia (less than 1.5 * 10 9 /L) 8 congestive heart failure at grade III or IV of the New York Heart Association (NYHA) 9 the past 3 months of visit to 1 had a major cardiovascular history, defined as: myocardial infarction Plug and coronary angioplasty or bypass surgery, valvular disease or repair, instability Angina pectoris, transient ischemic attack, or cerebrovascular accident 10 non well controlled atrial fibrillation 11 diagnosis of malignant tumors over the past 5 years 12 history of medullary thyroid carcinoma 13 organ transplantation or AIDS history 14 severe exophthalmos has influenced visual acuity 15 over the last 12 months, there is a history of alcohol abuse or drug abuse

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xijing Hospital, Fourth Military Medical university Xi'an Shaanxi China 710032

Sponsors and Collaborators

  • Xijing Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT03444246
Other Study ID Numbers:
  • KY20172032-1
First Posted:
Feb 23, 2018
Last Update Posted:
Feb 23, 2018
Last Verified:
Dec 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2018